A novel synthetic Piper amide derivative NED ‐180 inhibits hyperpigmentation by activating the PI 3K and ERK pathways and by regulating Ca 2+ influx via TRPM 1 channels

Piper amides have a characteristic, unsaturated amide group and exhibit diverse biological activities, including proliferation and differentiation of melanocytes, although the molecular mechanisms underlying its antimelanogenesis effect remain unknown. We screened a selected chemical library of newly synthesized Piper amide derivatives and identified (E)‐3‐(4‐(tert‐butyl)phenyl)‐N‐(2,3‐dihydrobenzo[b][1,4]dioxin‐6‐yl)acrylamide ( NED ‐180) as one of the most potent compounds in suppressing melanogenesis. In murine melan‐a melanocytes, NED ‐180 downregulated the expression of melanogenic regulatory proteins including tyrosinase, Tyrp1, Dct, and MITF . PI 3K/Akt‐dependent phosphorylation of GSK 3 β by NED ‐180 decreases MITF phosphorylation and inhibits melanogenesis without any effects on cytotoxicity and proliferation. Furthermore, topical application of NED ‐180 significantly ameliorated UVB ‐induced skin hyperpigmentation in guinea pigs. Interestingly, data obtained using calcium imaging techniques suggested that NED ‐180 reduced the TPA ‐induced activation of TRPM 1 (melastatin), which could explain the NED ‐180‐induced inhibition of melanogenesis. All things taken together, NED ‐180 triggers activation of multiple pathways, such as PI 3K and ERK , and inhibits TRPM 1/ TRPV 1, leading to inhibition of melanogenesis.